Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy

William Busse, Monica Kraft

Research output: Contribution to journalReview articlepeer-review

135 Scopus citations


Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

Original languageEnglish (US)
Pages (from-to)1312-1326
Number of pages15
Issue number4
StatePublished - Apr 2005


  • Asthma
  • Cytokines
  • Eosinophils
  • Inflammation
  • Leukotriene receptor antagonists
  • Leukotrienes
  • Remodeling
  • Rhinitis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Cysteinyl leukotrienes in allergic inflammation: Strategic target for therapy'. Together they form a unique fingerprint.

Cite this